Cordoniq Announces Qwen3 Integration to Empower AI-Driven Business Processes & Collaborations
SYRACUSE, N.Y.--(BUSINESS WIRE)-- Cordoniq, the secure, vision AI-driven platform for business processes and collaborations, today announced its new integration with Alibaba Cloud's Qwen3, the latest breakthrough in AI technology. This integration marks the beginning of a series of significant milestones in Cordoniq's mission to empower organizations with cutting-edge AI-driven solutions to deliver interactive, cohesive live experiences that enhance user engagement and intelligence.
First in series of multimodal AI milestones, Cordoniq redefines business processes and secure collaborations with cutting-edge interactive, cohesive live experiences.
Share
Companies can integrate the AI modal generative output back into the user experience, for interactive and real-time intelligence, for a cohesive, broader and more engaging live experience.
Qwen3, Alibaba Cloud's newest AI model, is renowned for its advanced multimodal capabilities, including text, image, video and audio processing, as well as enhanced natural language understanding and reasoning. By integrating Qwen3 into its platform, Cordoniq will deliver a seamless experience that combines secure business processes and collaborations with real-time analytics and interactive AI outputs. This integration enables organizations to benefit from features such as vision-language modeling, AI-generated creative content, and real-time data interpretation—all within Cordoniq's robust and secure framework.
'Our integration with Qwen3 is a game-changer for businesses looking to leverage the cutting-edge technology of multimodal AI,' said Allen Drennan, Co-founder & Principal, Cordoniq. 'By combining Qwen3's unparalleled capabilities with Cordoniq's secure business processes and collaborations, we are empowering companies to achieve faster decision-making, deeper insights, and more engaging live interactions—all while maintaining military-grade security standards.'
Key Benefits:
Product Innovation: Teams can use AI to develop new products where no prior data exists, accelerating time-to-market.
Hyper-Specific Customization: Organizations can leverage their unique data inputs to generate new value from their data, allowing them to fine tune AI models for their specific needs.
Simulated Market Exploration: Organizations can explore potential new markets and scenarios using synthetic data and AI-driven simulations.
Enhanced Collaboration: Cordoniq's secure-by-design platform ensures seamless integration of Qwen3 while maintaining military-grade security and privacy.
Open Source & Commercial AI Integration: Companies can securely integrate with both open source and commercial AI models, whether in a public or private cloud or on-premises.
OpenAI API Utilization: Cordoniq utilizes OpenAI's API to integrate directly with ChatGPT, Google Gemini and Alibaba Cloud's Qwen3 and feeds input data from a variety of sources - video, audio, images, text, documents, web content and more. The technology transcodes this data in real-time into formats that are compatible with a variety of AI models. These integrations allow for information to flow bi-directionally and in real-time.
Use Cases
'Cordoniq's pre-developed frameworks accelerate time-to-market while maintaining agile and powerful AI integration for business intelligence applications,' added Drennan. 'By incorporating Qwen3's generative outputs into user experiences, organizations can achieve cohesive and interactive live engagements that redefine collaboration standards.'
About Cordoniq
Cordoniq is a secure, vision AI-driven platform that empowers organizations by integrating multimodal AI into business processes and collaborations. By leveraging real-time analytics and AI-generated outputs, Cordoniq delivers interactive, cohesive live experiences that enhance user engagement and data intelligence.
Cordoniq provides pre-developed frameworks to accelerate time-to-market while ensuring nimble and powerful AI integration - from training, collaboration, governance, risk and compliance sessions - as well as many other use cases.
For more information, please visit www.cordoniq.com or join the conversation at LinkedIn, Facebook, and X.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
35 minutes ago
- Business Wire
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit
Yahoo
an hour ago
- Yahoo
2Modern Welcomes Nicole Andrew as Chief Marketing Officer
MILL VALLEY, Calif., June 05, 2025--(BUSINESS WIRE)--2Modern, a leading retailer for modern design since 2003, proudly announces the appointment of Nicole Andrew as Chief Marketing Officer (CMO). Reporting directly to CEO Greg Finney, Andrew joins the executive leadership team with 17 years in luxury retail & e-commerce marketing and merchandising, including a deep expertise in the design industry. As CMO, Andrew will lead all aspects of marketing, including brand strategy, performance marketing, creative, partnerships, and customer acquisition and retention. Her focus will be on accelerating growth and enhancing the customer experience, marking a pivotal moment as 2Modern enters a new chapter of expansion in the premium design space. Andrew most recently served as Chief Marketing Officer at Perigold, where she played a key role in shaping the brand's identity and driving significant growth over her eight year tenure. Her leadership, strategic vision, and digital expertise helped position Perigold as a standout in luxury e-commerce. "We're thrilled to welcome Nicole to the 2Modern leadership team," said CEO Greg Finney. "Her track record of building strong brands and her deep passion for design make her a perfect fit for our next stage of growth." "I'm incredibly excited to join 2Modern at such a dynamic time," said Andrew. "In just a few weeks, we've already begun reimagining the customer journey, strengthening storytelling across channels, and identifying new opportunities for growth. I've long admired 2Modern's commitment to authentic, elevated design and look forward to building on that legacy." About 2Modern 2Modern is a leading retailer of modern furniture, lighting, and home accessories, dedicated to bringing timeless design into contemporary living spaces. Established in 2003, 2Modern is focused on partnering with iconic and emerging global design brands to inspire customers and elevate interiors through thoughtful, forward-thinking design. For more information, please visit and follow @2modern on Instagram, Facebook, and Pinterest. View source version on Contacts press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
